Archive: November 2025

INOVIO Announces Pricing of $25 Million Public Offering

Posted on November 11, 2025

INOVIO Announces Proposed Public Offering

Posted on November 10, 2025

INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Posted on November 10, 2025

INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults

Posted on November 3, 2025

INOVIO Reports Inducement Grant Under Inducement Plan

Posted on October 31, 2025

INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025

Posted on October 27, 2025

INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference

Posted on October 23, 2025

Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine

Posted on October 21, 2025

INOVIO Reports Inducement Grant Under Inducement Plan

Posted on October 2, 2025

INOVIO to Participate in Upcoming Scientific Conferences

Posted on September 25, 2025

© Copyright 2026 INOVIO Pharmaceuticals. All rights reserved.